Compare PPC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPC | BLTE |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 52100 | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.0B |
| IPO Year | 1997 | 2021 |
| Metric | PPC | BLTE |
|---|---|---|
| Price | $28.75 | $158.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $33.29 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 1.4M | 117.1K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $18,497,553,000.00 | N/A |
| Revenue This Year | $0.27 | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | $59.48 | ★ N/A |
| Revenue Growth | ★ 3.46 | N/A |
| 52 Week Low | $25.13 | $78.71 |
| 52 Week High | $44.84 | $200.00 |
| Indicator | PPC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 44.29 |
| Support Level | $27.28 | $158.32 |
| Resistance Level | $29.90 | $161.10 |
| Average True Range (ATR) | 0.99 | 5.48 |
| MACD | 0.16 | -1.50 |
| Stochastic Oscillator | 90.07 | 33.91 |
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.